Catalent in deal to buy gene therapy contract manufacturer Paragon for $1.2B
The deal follows by weeks Thermo Fisher's acquisition, for $1.7 billion, of gene therapy contract manufacturing organization Brammer Bio.
Paragon Bioservices raises $13M to expand CRO/CMO work in vaccines, biologics
Paragon Bioservices – a contract research and manufacturing organization, has closed a $13 million round of Series A financing. The Baltimore company’s focused on biologics and vaccine work. The financing was led by NewSpring Capital and Camden Partners. Paragon CEO Marco Chacon described the fundraise as indicative of “an inflection point for the company,” now that […]
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.